---
title: "CRISPR-Based Rapid Diagnostics for Antimicrobial Resistance"
created: 2026-06-07
updated: 2026-06-07
type: concept
tags: [microbiology, technique, bioinformatics, emerging-diseases]
sources:
  - type: paper
    url: "https://pubmed.ncbi.nlm.nih.gov/34863214/"
    title: "Engineered CRISPR-Cas systems for the detection and control of antibiotic-resistant infections"
    date: "2022-05"
  - type: paper
    url: "https://pubmed.ncbi.nlm.nih.gov/40992601/"
    title: "CRISPR for detection of drug resistance genes"
    date: "2024"
  - type: paper
    url: "https://pubmed.ncbi.nlm.nih.gov/39906792/"
    title: "New frontiers in CRISPR: Addressing antimicrobial resistance with Cas9, Cas12, Cas13, and Cas14"
    date: "2025"
  - type: paper
    url: "https://pubmed.ncbi.nlm.nih.gov/41988391/"
    title: "Applications and Challenges of CRISPR-Cas Technology for the Detection of Antimicrobial Resistance Genes"
    date: "2025"
  - type: paper
    url: "https://pubmed.ncbi.nlm.nih.gov/33148705/"
    title: "SHERLOCK and DETECTR: CRISPR-Cas Systems as Potential Rapid Diagnostic Tools for Emerging Infectious Diseases"
    date: "2021-01"
  - type: paper
    url: "https://pubmed.ncbi.nlm.nih.gov/33839288/"
    title: "CRISPR-Cas systems for diagnosing infectious diseases"
    date: "2021-05"
  - type: paper
    url: "https://pubmed.ncbi.nlm.nih.gov/40311721/"
    title: "CRISPR revolution: Unleashing precision pathogen detection to safeguard public health and food safety"
    date: "2025"
  - type: paper
    url: "https://pubmed.ncbi.nlm.nih.gov/36421156/"
    title: "CRISPR-Cas-Integrated LAMP"
    date: "2022-11"
  - type: paper
    url: "https://pubmed.ncbi.nlm.nih.gov/38861812/"
    title: "A TdT-driven amplification loop increases CRISPR-Cas12a DNA detection levels"
    date: "2024-05"
  - type: paper
    url: "https://pubmed.ncbi.nlm.nih.gov/34653714/"
    title: "Exploiting orthogonal CRISPR-Cas12a/Cas13a trans-cleavage for dual-gene virus detection using a handheld device"
    date: "2022-01"
  - type: paper
    url: "https://pubmed.ncbi.nlm.nih.gov/40419416/"
    title: "Exploring a CRISPR/Cas12a-powered impedimetric biosensor for amplification-free detection of pathogenic bacterial DNA"
    date: "2024-08"
  - type: paper
    url: "https://pubmed.ncbi.nlm.nih.gov/35696867/"
    title: "A CRISPR-Cas12a-powered magnetic relaxation switching biosensor for the sensitive detection of Salmonella"
    date: "2022-09"
  - type: paper
    url: "https://pubmed.ncbi.nlm.nih.gov/32800128/"
    title: "CRISPR-Cas13a based bacterial detection platform: Sensing pathogen Staphylococcus aureus in food samples"
    date: "2020-09"
  - type: paper
    url: "https://pubmed.ncbi.nlm.nih.gov/38057050/"
    title: "Electrochemical biosensing for E.coli detection based on triple helix DNA inhibition of CRISPR/Cas12a cleavage activity"
    date: "2024-01"
  - type: paper
    url: "https://pubmed.ncbi.nlm.nih.gov/36843874/"
    title: "Aptamer-based CRISPR-Cas powered diagnostics of diverse biomarkers and small molecule targets"
    date: "2023-01"
  - type: paper
    url: "https://pubmed.ncbi.nlm.nih.gov/33321741/"
    title: "A CRISPR/Cas12a Based Universal Lateral Flow Biosensor for the Sensitive and Specific Detection of African Swine-Fever Viruses in Whole Blood"
    date: "2021-01"
  - type: paper
    url: "https://pubmed.ncbi.nlm.nih.gov/34049081/"
    title: "Cas14a1-mediated nucleic acid detection platform for pathogens"
    date: "2021-05"
  - type: paper
    url: "https://pubmed.ncbi.nlm.nih.gov/37505456/"
    title: "Aerosol Jet Printing-Enabled Dual-Function Electrochemical and Colorimetric Biosensor for SARS-CoV-2 Detection"
    date: "2023-08"
  - type: paper
    url: "https://pubmed.ncbi.nlm.nih.gov/40685330/"
    title: "CRISPR Technology in Disease Management: An Updated Review of Clinical Translation and Therapeutic Potential"
    date: "2025-01"
  - type: paper
    url: "https://pubmed.ncbi.nlm.nih.gov/32939188/"
    title: "CRISPR-Based Diagnosis of Infectious and Noninfectious Diseases"
    date: "2020-06"
  - type: paper
    url: "https://pubmed.ncbi.nlm.nih.gov/33428981/"
    title: "CRISPR systems: Novel approaches for detection and combating COVID-19"
    date: "2021-05"
confidence: high
contested: false
---

# CRISPR-Based Rapid Diagnostics for Antimicrobial Resistance

## Overview

CRISPR-Cas systems repurposed from genome editing into diagnostic platforms [1,6]. Cas12, Cas13, and Cas14 exhibit **collateral cleavage** — promiscuous nuclease activity on non-target ssDNA/ssRNA after binding their specific target — enabling signal amplification without thermal cycling [1,5].

## Mechanism

- **Cas12 (Type V):** DNA-guided → collateral ssDNA cleavage. PAM: TTVV. Variants: Cas12a/Cpf1, Cas12b, Cas12f [1,3]
- **Cas13 (Type VI):** RNA-guided → collateral ssRNA cleavage. PAM-independent. Variants: Cas13a/C2c2, Cas13b/C2c3 [1,6]
- **Cas14:** ssDNA targeting without PAM. ~700 aa, compact for AAV delivery [3,17]

## Major Platforms[5,6]

| Platform | Enzyme | Developer | Sensitivity | Time | Readout |
|----------|--------|-----------|-------------|------|---------|
| SHERLOCK v2 | Cas13a | Broad Institute / Sherlock Biosciences (OraSure) | 5 aM | 30 min | Lateral flow / fluorescence [5] |
| DETECTR | Cas12a | UC Berkeley / Mammoth Biosciences | 1 aM | 30 min | Lateral flow [5,6] |
| HOLMES-HR | Cas12a | Doudna lab | ~10 aM | 45 min | Lateral flow [5] |

## AMR Detection Targets[2,4]

- **Carbapenemases:** bla_KPC, bla_NDM-1, bla_CTX-M (WHO critical priority) [2,4]
- **MRSA:** mecA gene detection [2,4]
- **VRE:** vanA/vanB screening [2,4]
- **ESBL:** bla_CTX-M family variants [2,4]

Clinical validation: 93-97% sensitivity, 97-99% specificity across published studies [2,4].

## Comparison with Existing Methods[1,6,19]

| Method | Time | Sensitivity | Equipment | Cost/test |
|--------|------|-------------|-----------|-----------|
| Culture + AST | 48-72h | Gold standard | Incubator, media | $10-30 [1] |
| PCR | 2-4h | High | Thermocycler | $20-50 [6] |
| WGS | 6-24h | Comprehensive | Sequencer + bioinformatics | $50-100 [19] |
| CRISPR diagnostic | 30-60 min | ~PCR-level | RPA heater or none (lateral flow) | $5-15 [7,19] |

## Key Challenges[2,4,19]

1. **Pre-amplification dependency** — Most assays require RPA/LAMP before Cas detection [3,8]
2. **Multiplexing limits** — 2-4 targets simultaneously; comprehensive AMR panels need sequential testing [4,7]
3. **Sample prep** — Clinical specimens contain inhibitors affecting both amplification and Cas activity [4,19]
4. **crRNA design for gene families** — bla_CTX-M has >200 variants requiring conserved-region targeting with single-nucleotide discrimination [2,4]
5. **Regulatory pathway** — No CRISPR AMR diagnostic has full FDA approval as of 2026 [19]

## Market Status[7,19]

- Global CRISPR diagnostics market: ~$2.1B projected by 2030 (CAGR ~25%) [7,19]
- AMR-specific segment: $350-500M by 2028 [7]
- **Sherlock Biosciences** acquired by OraSure Technologies (Dec 2024) [7]
- **Mammoth Biosciences** pursuing FDA clearance for infectious disease + AMR panels [19]

## Future Directions[3,7,9,15]

- Amplification-free detection via TdT-driven loops and hyperactive Cas variants [9,11]
- Microfluidic integration (sample-to-answer in single cartridge) [7,18]
- AI-guided crRNA design for rapid assay development against emerging resistance genes [3,15]

## Related

[Crispr Cas9](crispr-cas9.md), [Antimicrobial Resistance](antimicrobial-resistance.md), [Next Generation Sequencing](next-generation-sequencing.md), [Metagenomics](metagenomics.md)

---

[1]: Raw article: [^raw/articles/crispr-amr-diagnostics-2026.md]
[2]: PMID:34863214, PMID:40992601, PMID:41988391
[3]: PMID:38861812 — TdT-driven amplification loop approach
[4]: PMID:40419416 — Amplification-free impedimetric biosensor
